Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug ...
Drug manufacturers Moderna and Merck say a personalized mRNA cancer vaccine plus a drug called Keytruda reduced the return ...
An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, in a large, closely watched ...
Combining a vaccine and immunotherapy approach could open new ways to treat cancer.
The combined drug works by nudging the body’s own immune system to make proteins that attack and destroy melanoma cells ...
Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment ...
The rally was primarily driven by the strong late-stage trial of Moderna Inc.’s (NASDAQ:MRNA) intismeran autogene—an ...
The announcement by Moderna Inc. and Merck & Co. that a messenger RNA-based cancer vaccine had lowered the recurrence rate ...
莫德纳位于马萨诸塞州剑桥市总部的一间实验室，摄于2024年。 Adam Glanzman/Bloomberg ...
Health officials say a potential new weapon in the fight against melanoma is showing promising results. Moderna and Merck say ...
"These corporations have learned how to play the medical-scientific establishment like a Stradivarius," Johns Hopkins ...
In light of recent wins for mRNA vaccine makers, UCSC RNA Center Co-Director Jeremy Sanford describes the versatility of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results